The Phase 3 clinical trial investigating CagriSema (Cagrilintide B and Semaglutide I) for people with Type 2 Diabetes completed its primary data collection on 2026-03-04. This study, which enrolled 1024 participants, compares CagriSema's efficacy in lowering blood sugar and body weight against tirzepatide.
Background
CagriSema is an investigational medicine being evaluated for the treatment of Type 2 Diabetes. It is a co-formulation of cagrilintide and semaglutide, and in this trial, it is being compared to tirzepatide, another established treatment option for the condition.
Trial design
The study, identified as NCT06221969, is a Phase 3 clinical trial. It enrolled 1024 participants diagnosed with Type 2 Diabetes who were treated with metformin with or without an SGLT2 inhibitor. The trial's objective is to assess how well CagriSema lowers blood sugar and body weight compared to tirzepatide. Participants were randomized to receive either CagriSema or tirzepatide over a period of up to one and a half years.
What this means
The primary completion of this Phase 3 trial for CagriSema marks a significant step towards understanding its potential role in managing Type 2 Diabetes. The comparison against tirzepatide, a current treatment, will provide crucial data on CagriSema's comparative efficacy in reducing blood sugar and body weight. Clinicians and patients await the full results to evaluate its potential as a new therapeutic option.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06221969, titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor," was posted on 2026-03-04 on clinicaltrials.gov.